Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kate Newbold

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
The Lancet. Diabetes & Endocrinology|December 4, 2018
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trialHakim-Moulay Dehbi, Ujjal Mallick, Jonathan Wadsley, et al.
Thyroid : Official Journal of the American Thyroid Association|December 4, 2025
A Systematic Review of Absorbed Doses and Response in Patients Treated with Radioiodine for Differentiated Thyroid CancerJan Taprogge, Iain Murray, Kate Newbold, et al.
The Journal of Clinical Endocrinology and Metabolism|March 16, 2013
Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancerLiam Welsh, Ceri Powell, Brenda Pratt, et al.
Frontiers in Oncology|October 7, 2021
Early-Stage Glottic Squamous Cell Carcinoma in the Era of Image-Guided RadiotherapyAmit Gupta, Kee Howe Wong, Kate Newbold, et al.
European Thyroid Journal|November 27, 2019
2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid CancerLaura Fugazzola, Rossella Elisei, Dagmar Fuhrer, et al.
International Journal of Radiation Oncology, Biology, Physics|April 28, 2009
Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysisPrasad Dandekar, Clive Harmer, Yolanda Barbachano, et al.
World Journal of Surgical Oncology|April 5, 2008
Thyroid cancer causing obstruction of the great veins in the neckSteve L Hyer, Prasad Dandekar, Kate Newbold, et al.
Current Cancer Drug Targets|March 6, 2010
The biology of the sodium iodide symporter and its potential for targeted gene deliveryMohan Hingorani, Christine Spitzweg, Georges Vassaux, et al.
Lancet (London, England)|April 6, 2023
Thyroid cancerDebbie W Chen, Brian H H Lang, Donald S A McLeod, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 18, 2009
A dose-effect correlation for radioiodine ablation in differentiated thyroid cancerGlenn D Flux, Masud Haq, Sarah J Chittenden, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
The Lancet. Diabetes & Endocrinology|December 4, 2018
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trialHakim-Moulay Dehbi, Ujjal Mallick, Jonathan Wadsley, et al.
Thyroid : Official Journal of the American Thyroid Association|December 4, 2025
A Systematic Review of Absorbed Doses and Response in Patients Treated with Radioiodine for Differentiated Thyroid CancerJan Taprogge, Iain Murray, Kate Newbold, et al.
The Journal of Clinical Endocrinology and Metabolism|March 16, 2013
Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancerLiam Welsh, Ceri Powell, Brenda Pratt, et al.
Frontiers in Oncology|October 7, 2021
Early-Stage Glottic Squamous Cell Carcinoma in the Era of Image-Guided RadiotherapyAmit Gupta, Kee Howe Wong, Kate Newbold, et al.
European Thyroid Journal|November 27, 2019
2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid CancerLaura Fugazzola, Rossella Elisei, Dagmar Fuhrer, et al.
International Journal of Radiation Oncology, Biology, Physics|April 28, 2009
Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysisPrasad Dandekar, Clive Harmer, Yolanda Barbachano, et al.
World Journal of Surgical Oncology|April 5, 2008
Thyroid cancer causing obstruction of the great veins in the neckSteve L Hyer, Prasad Dandekar, Kate Newbold, et al.
Current Cancer Drug Targets|March 6, 2010
The biology of the sodium iodide symporter and its potential for targeted gene deliveryMohan Hingorani, Christine Spitzweg, Georges Vassaux, et al.
Lancet (London, England)|April 6, 2023
Thyroid cancerDebbie W Chen, Brian H H Lang, Donald S A McLeod, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 18, 2009
A dose-effect correlation for radioiodine ablation in differentiated thyroid cancerGlenn D Flux, Masud Haq, Sarah J Chittenden, et al.
Pageof 8